Tag: Abemaciclib

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Abemaciclib

Global Cancer CDK Inhibitor Market 2019-2029 - Pipeline Analysis is estimated to be US$ 16.1 ...

Added to Collection on: 2021-03-17 15:33:45

Tags for this article:

Chemical compounds
Protein kinase inhibitors
Organic compounds
Piperazines
Cell cycle
Breakthrough therapy
Cyclopentanes
CDK inhibitor
Palbociclib
Cyclin-dependent kinase
Novartis
Abemaciclib

Click the tags to see associated articles and topics

View Article Details
Data Leading Up to the Next MONARCH 1 Analysis in mBC

Added to Collection on: 2021-05-03 17:48:45

Tags for this article:

Chemical compounds
Organic compounds
Protein kinase inhibitors
Piperazines
Breakthrough therapy
Pyridines
Cyclopentanes
Abemaciclib
Palbociclib
Cyclin-dependent kinase
Tamoxifen
Ribociclib
Sarah Cannon Research Institute

Click the tags to see associated articles and topics

View Article Details
Validation for a drug class, and for Sanofi

Added to Collection on: 2021-05-12 14:26:15

Tags for this article:

Chemical compounds
Organic compounds
Protein kinase inhibitors
Antiestrogens
Piperazines
Cyclopentanes
Breakthrough therapy
Selective estrogen receptor degrader
Palbociclib
Fulvestrant
Ribociclib
Abemaciclib

Click the tags to see associated articles and topics

View Article Details
Novartis, determined to dethrone Pfizer, will launch bold Kisqali-Ibrance head-to-head trial ...

Added to Collection on: 2021-09-19 15:00:00

Tags for this article:

Chemical compounds
Organic compounds
Protein kinase inhibitors
Piperazines
Cyclopentanes
Breakthrough therapy
Pyridines
Palbociclib
Ribociclib
Triple-negative breast cancer
Cyclin-dependent kinase 4
Abemaciclib
Novartis
Ibrance

Click the tags to see associated articles and topics

View Article Details
New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with ...

Added to Collection on: 2022-06-03 16:23:40

Tags for this article:

Chemical compounds
Organic compounds
Protein kinase inhibitors
Piperazines
Cyclopentanes
Pyridines
Breakthrough therapy
Ribociclib
Palbociclib
Breast cancer
Astex Pharmaceuticals
Abemaciclib
Letrozole
Novartis AG

Click the tags to see associated articles and topics

View Article Details
Hope S. Rugo, MD, on Comparing CDK4/6 Inhibitors in HR+/HER2– Advanced Breast Cancer

Added to Collection on: 2022-07-24 14:03:55

Tags for this article:

Chemical compounds
Protein kinase inhibitors
Piperazines
Pyridines
Cyclopentanes
Breakthrough therapy
Ribociclib
Abemaciclib
Breast cancer
Hope Rugo
Aromatase inhibitor
American Society of Clinical Oncology

Click the tags to see associated articles and topics

View Article Details
Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4 ...

Added to Collection on: 2022-09-11 00:27:34

Tags for this article:

Chemical compounds
Organic compounds
Protein kinase inhibitors
Piperazines
Cyclopentanes
Breakthrough therapy
Pyridines
Palbociclib
Ribociclib
CDK inhibitor
Abemaciclib
Letrozole

Click the tags to see associated articles and topics

View Article Details
After setbacks for Roche and Sanofi, AZ scores oral SERD win - - Pharmaphorum

Added to Collection on: 2022-10-26 10:23:01

Tags for this article:

Chemical compounds
Organic compounds
Drugs
Antiestrogens
Protein kinase inhibitors
Piperazines
Breakthrough therapy
Selective estrogen receptor degraders
Palbociclib
Abemaciclib
Fulvestrant
Elacestrant
Faslodex

Click the tags to see associated articles and topics

View Article Details
MonarchE Update Benefit of Abemaciclib Increases Over Time - The ASCO Post

Added to Collection on: 2022-12-11 15:46:43

Tags for this article:

Chemical compounds
Protein kinase inhibitors
Chemistry
Clinical medicine
Breakthrough therapy
Piperazines
Abemaciclib
Benzimidazoles
Pyridines
Adjuvant therapy
Breast cancer
Stephen R.D. Johnston

Click the tags to see associated articles and topics

View Article Details
Palbociclib by Pfizer for Mantle Cell Lymphoma: Likelihood of Approval

Added to Collection on: 2023-12-26 17:13:01

Tags for this article:

Aminopyridines
Breast cancer
Lactams
Palbociclib
HER2
Fulvestrant
Metastatic breast cancer
Chemotherapy regimen
Transitional cell carcinoma
CDK inhibitor
Abemaciclib
PD-0332991
Pfizer

Click the tags to see associated articles and topics

View Article Details